Lung Cancer
Volume 55, Issue 1 , Pages 125-127 , January 2007

Gefitinib in the treatment of elderly patients with advanced non-small cell lung cancer (NSCLC)

Received 19 April 2006

References 

  1. Janssen-Hejnen MLG, Schipper RM, Razenberg PPA, Crommelin MA, Coebergh JW. Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: a population-based study. Lung Cancer. 1998;21:105–113
  2. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. Multi-institutional randomised phase II trial of Gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol. 2003;21:2237–2246
  3. Natale RB, Skarin AT, Maddox AM, Hammond LA, Thomas R, Gandara DR, et al. Improvement in symptoms and quality of life for advanced non small-cell lung cancer patients receiving ZD1839 (‘Iressa’) in IDEAL 2. In: Proceeding of American Society of Clinical Oncolology 21. Orlando, FL, May 18–21. 2002;[Abstract no. 1167]
  4. Cella D, Herbst RS, Lynch TJ, Prager D, Belani CP, Schiller JH, et al. Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving Gefitinib in a randomized controlled trial. J Clin Oncol. 2005;23:2946–2954
  5. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsch V, Thongprasert S, et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med. 2005;353:123–132
  6. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to Gefitinib. N Engl J Med. 2004;350:2129–2139
  7. Miller Va , Kris MG, Shah N, Patel J, Azzoli C, Gomez J, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity yo Gefitinib in advanced non small cell lung cancer. J Clin Oncol. 2004;22:1103–1109
  8. Cella DF, Bonomi AE, Lloyd SR, Tulsky DS, Kaplan E, Bonomi P, et al. Reliability and validity of the Functional Assessment of Cancer-Therapy Lung (FACT-L) quality of life instrument. Lung Cancer. 1995;12:199–220
  9. Gridelli C, Maione P, Castaldo V, Rossi A. Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer. Br J Cancer. 2003;89:1827–1829
  10. Cappuzzo F, Bartolini S, Ceresoli GL, Tamberi S, Spreafico A, Lombardo L, et al. Efficacy and tolerability of Gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC). Br J Cancer. 2004;90:82–86

PII: S0169-5002(06)00525-3

doi: 10.1016/j.lungcan.2006.09.017

Lung Cancer
Volume 55, Issue 1 , Pages 125-127 , January 2007

Article Tools